Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizable portion of the Chinese population every year. With the introduction of proteasome inhibitors and immunomodulatory agents in China, the median overall survival has seen much improvement over the last decade. The multiple myeloma market of China is expected to expand further over the 2020-2030 period, fueled by the increasing disease incidence and an increasing uptake of targeted agents—most notably that of the recently launched daratumumab and upcoming carfilzomib, selinexor and isatuximab—owing to their potential efficacy in improving the progression-free survival (PFS) in patients, especially in the relapsed / refractory setting. Despite the availability of several traditional and novel agents over the forecast period, high unmet need will remain for therapies that can significantly improve patients’ PFS and overall survival (OS), representing an opportunity for new drug developers. Additionally, with the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies are likely to be increasingly incentivized to enter the multiple myeloma market of China.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Diagnosed incidence of multiple myeloma in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
Annualized, 10-year, drug-level sales and patient share of key multiple myeloma therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III / PR: 7 drugs; Phase II: 5 drugs; coverage of select Phase I products.